Suven Life Sciences declined 9.91% to Rs 28.65 at 14:39 IST on BSE even as the company said it has secured patent rights for two of its new chemical entities for the treatment of disorders associated with neurodegenerative diseases.
The company made this announcement during trading hours today,
The stock hit a high of Rs 31.80 and a low of Rs 28.65 so far during the day. The stock had a 52-week high of Rs 64.45 on
The company’s current equity is Rs 11.57 crore. Face value per share is Rs 1.
The current price of Rs 28.65 discounts its Q3 December 2007 annualized EPS of Rs 0.70, by a PE multiple of 40.93.
The patents are valid till 2023. The patents are valid in all contracting countries like
Suven Life Sciences net profit declined 47.5% to Rs 2.01 crore on 12% fall in net sales to Rs 27.46 crore in Q3 December 2007 over Q3 December 2006.
Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the
No comments:
Post a Comment